Galenica reports a revenue increase of 4.7% for Q3 2025, driven by its acquisition of Labor Team and strong demand for prescription medications.

Information on the Target

As of the end of September 2025, Galenica has recorded a revenue of CHF 2,999.7 million, continuing its growth trajectory in the third quarter. This represents an increase of 4.7%, driven equally by its segments 'Products & Care' (+5.0%) and 'Logistics & IT' (+5.0%). The company's growth aligns with the overall market's performance, as the pharmaceutical market experienced a growth of 5.1% during the same period, while the consumer healthcare market saw a slight decline of 0.4%.

In the first half of 2025, Galenica reported a revenue increase of 5.0%. Although the growth rate softened in the third quarter, mainly due to a strong comparative period, demand for prescription medications, particularly GLP-1-based weight loss drugs and dietary supplements, continues to fuel this progress.

Industry Overview in Switzerland

The Swiss pharmaceutical market remains resilient, reflecting a growth rate of 5.1% in the third quarter of 2025. This growth surpasses the global average for pharmaceutical industries, indicating a robust demand fo